Relapsing Thrombotic Thrombocytopenic Purpura (TTP) in a Patient Treated with Infliximab for Chronic Uveitis

Ocul Immunol Inflamm. 2022 Jan 2;30(1):241-243. doi: 10.1080/09273948.2020.1797117. Epub 2020 Sep 18.

Abstract

Purpose: To report a case of relapsing thrombotic thrombocytopenic purpura (TTP) in a patient treated with infliximab for chronic uveitis.

Case report: A 57-year-old African American woman with chronic anterior and intermediate uveitis, treated with infliximab for more than 1 year, presented with fatigue, dark colored urine, and ecchymosis on her extremities. She was diagnosed with thrombotic thrombocytopenic purpura (TTP) and recovered after treatment. After a remission period of 8 months, she was treated again with infliximab for recurrent intraocular inflammation. She developed a relapse of TTP 4 weeks after reintroducing infliximab.

Conclusion: Relapsing thrombotic thrombocytopenic purpura can be a rare complication associated with infliximab. To our knowledge, it has not been reported in the literature to date.

Keywords: ADAMTS13; Thrombotic thrombocytopenic purpura; drug-induced thrombotic microangiopathy; infliximab; uveitis.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Humans
  • Infliximab / adverse effects
  • Middle Aged
  • Purpura, Thrombotic Thrombocytopenic* / chemically induced
  • Purpura, Thrombotic Thrombocytopenic* / diagnosis
  • Purpura, Thrombotic Thrombocytopenic* / drug therapy
  • Recurrence

Substances

  • Infliximab